Low-Dose IV Buprenorphine vs Hydromorphone for Acute Pain in the ED

November 10, 2026 updated by: Terry Lee Ahern, Stanford University

Low-Dose Buprenorphine Compared With Hydromorphone for Acute Pain in the Emergency Department: A Pragmatic Noninferiority Randomized Clinical Trial

The goal of this study is to compare low-dose IV buprenorphine with IV hydromorphone for adults with undifferentiated acute pain in the Stanford Emergency Department.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

136

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Stanford, California, United States, 94305
        • Stanford Emergency Department

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Presenting to the Stanford Emergency Department with acute undifferentiated pain
  • The treating emergency physician determines that IV opioid analgesia equivalent to 0.5 mg IV hydromorphone is indicated
  • Ability to provide informed consent and serial pain assessments

Exclusion Criteria:

  • Primary headache
  • Contraindication to either study medication
  • Pregnancy
  • Inability to provide informed consent or serial pain assessments
  • Immediate need for procedural sedation or airway management
  • Opioid analgesia already received for the current pain episode
  • Daily scheduled opioid therapy
  • Maintenance treatment with buprenorphine or methadone

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Buprenorphine

The participants receive a single intravenous (IV) 90 mcg dose of Buprenorphine for acute pain in the emergency department (ED). Rescue IV hydromorphone 0.5 mg may be administered after 30 minutes if needed for acute pain.

Buprenorphine is a partial mu-opioid receptor agonist with a ceiling effect on respiratory depression and a longer duration of action than full agonists.

Other Names:
  • Buprenex
Active Comparator: Hydromorphone

The participants receive a single IV dose of 0.5 mg hydromorphone for acute pain in the ED. Rescue IV hydromorphone 0.5 mg may be administered after 30 minutes if needed for acute pain.

Hydromorphone is a full mu-opioid receptor agonist and a commonly used standard IV opioid analgesic in emergency department practice.

Other Names:
  • Dilaudid

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in pain intensity on the 0-10 Numeric Rating Scale (NRS)
Time Frame: Baseline (pre-randomization), and up to 60 minutes after drug administration

Pain intensity is rated on the 0-10 NRS (0 = no pain, 10 = worst pain imaginable). Outcome is the change score (60-minute NRS minus baseline NRS), with a more negative change indicating greater pain relief.

Baseline (pre-randomization), and up to 60 minutes after drug administration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Terence Ahern, MD, Stanford University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2027

Primary Completion (Estimated)

July 1, 2028

Study Completion (Estimated)

July 1, 2028

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.